Imfinzi: Clinical Trials

124 trials of Imfinzi, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

35 active not recruiting, 29 recruiting, 19 terminated, 18 completed. 124 Phase 2, 20 Phase 1, 4 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2124Active not recruiting 35, Recruiting 29, Terminated 19, Completed 18, Withdrawn 9, Not yet recruiting 7, Unknown 5, Enrolling by invitation 1, Suspended 1
Phase 120Active not recruiting 7, Terminated 6, Completed 3, Recruiting 2, Unknown 2
Phase 34Completed 2, Not yet recruiting 1, Recruiting 1

Follow Imfinzi: new trials by email Literature Review of Imfinzi trials Research Report on Imfinzi

Trials (filtered) newest first · largest first

All 124 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Preoperative Durvalumab, Cisplatin, Gemcitabine With or Without Futibatinib Targeted Therapy for the Treatment of Resectable Intrahepatic Cholangiocarcinoma, OPTIC Trial
Biospecimen Collection, Cisplatin, Computed Tomography - Resectable Intrahepatic Cholangiocarcinoma
Phase 2Not yet recruitingNorthwestern University442027-12-102026-06-10
Testing the Addition of Ivonescimab Combined With Standard Chemotherapy Compared to the Usual Chemotherapy and Immunotherapy Treatment for Patients With Advanced Biliary Tract Cancer
Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Biliary Tract Adenocarcinoma, Locally Advanced Extrahepatic Cholangiocarcinoma
Phase 2 / Phase 3Not yet recruitingECOG-ACRIN Cancer Research Group3362027-01-112026-08-14
Alternating Chemo-immunotherapy and FGFR Inhibitor for FGFR-positive Biliary or Cholangiocarcinoma
Biospecimen Collection, Cisplatin, Computed Tomography - Locally Advanced Ampulla of Vater Carcinoma, Locally Advanced Biliary Tract Carcinoma
Phase 2RecruitingOhio State University Comprehensive Cancer Center292026-11-012026-09-10
A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma
Tremelimumab, Durvalumab, Gemcitabine - Combined Hepatocellular and Cholangiocarcinoma
Phase 2Not yet recruitingMehmet Akce292026-11-012026-11-04
A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC
Lurbinectedin, Durvalumab - Extensive-stage Small-cell Lung Cancer
Phase 2RecruitingJazz Pharmaceuticals502026-10-122026-11-06
Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT)
Biological: Fecal Microbiota Transplantation, Durvalumab, Paclitaxel - Non Small Cell Lung Cancer, Respiratory Tract Neoplasm
Phase 2Not yet recruitingFundación GECP682026-09-152026-05-05
TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma
Durvalumab - Esophagogastric Adenocarcinoma
Phase 2Not yet recruitingInstitut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest1012026-07-012026-04-02
Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
Sacituzumab govitecan, Atezolizumab, Durvalumab - Small Cell Lung Cancer ( SCLC ), Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Phase 2RecruitingBindu R Potugari352026-05-142026-07-28
Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
Adagrasib, Anti-PD-L1 Monoclonal Antibody, Anti-PD1 Monoclonal Antibody - Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8
Phase 2RecruitingCity of Hope Medical Center5352026-05-012026-10-16
Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma
Angiogram, Biopsy Procedure, Biospecimen Collection - Locally Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8
Phase 2Not yet recruitingOHSU Knight Cancer Institute402026-04-022026-04-06
A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement
Pemigatinib, Durvalumab - Intrahepatic Cholangiocarcinoma, FGFR2 Gene Rearrangement
Phase 2RecruitingMehmet Akce382026-01-272026-10-05
Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study
Biospecimen Collection, Ceralasertib, Computed Tomography - Extensive Stage Lung Small Cell Carcinoma, Lung Small Cell Carcinoma, A Subtype
Phase 2RecruitingSWOG Cancer Research Network9002025-11-062026-03-30
Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer
Atezolizumab, Biopsy Procedure, Biospecimen Collection - Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Phase 1 / Phase 2RecruitingNational Cancer Institute (NCI)452025-04-082026-11-16
Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS
Albumin-Bound Paclitaxel, Epirubicin, Gemcitabine - Rare Tumour
Phase 2Not yet recruitingPeking University Shenzhen Hospital2002025-01-012024-11-18
Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy
Biospecimen Collection, Computed Tomography, Durvalumab - Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma
Phase 2RecruitingYuanquan Yang242024-12-302026-10-01
Zanzalintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepatocellular Carcinoma (ZENOBIA)
Zanzalintinib, Durvalumab, Tremelimumab - Hepatocellular Carcinoma
Phase 2RecruitingAnwaar Saeed402024-12-182026-11-13
Study of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocellular Carcinomas With Child-Pugh-B Cirrhosis
Tremelimumab, Durvalumab - Hepatocellular Carcinoma, Cirrhosis, Liver
Phase 2RecruitingThe University of Texas Health Science Center at San Antonio322024-12-022026-01-06
Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)
Durvalumab, Olaparib - Small Cell Lung Carcinoma
Phase 2Enrolling by invitationUniversity of Cologne292024-10-092025-05-20
Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP)
Durvalumab, Olaparib - Cholangiocarcinoma
Phase 2RecruitingAustralasian Gastro-Intestinal Trials Group402024-09-232026-05-06
Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC
RP2, Bevacizumab, Atezolizumab - Hepatocellular Carcinoma, Biliary Tract Cancer
Phase 2RecruitingReplimune, Inc.602024-08-012026-04-02

Showing 20 of 124. Sign in to see all of them.

Conditions studied

Carcinoma, Non-Small-Cell Lung (24)  ·  Lung Neoplasms (19)  ·  Carcinoma, Hepatocellular (10)  ·  Cholangiocarcinoma (10)  ·  Small Cell Lung Carcinoma (10)  ·  Urinary Bladder Neoplasms (7)  ·  Pancreatic Neoplasms (6)  ·  Biliary Tract Neoplasms (5)  ·  Squamous Cell Carcinoma of Head and Neck (5)  ·  Breast Neoplasms (4)  ·  Colorectal Neoplasms (4)  ·  Bile Duct Neoplasms (3)  ·  Carcinoma, Renal Cell (3)  ·  Carcinoma, Transitional Cell (3)  ·  Fallopian Tube Neoplasms (3)

Sponsors

National Cancer Institute (NCI) (13)  ·  M.D. Anderson Cancer Center (12)  ·  University Health Network, Toronto (5)  ·  Mayo Clinic (4)  ·  University of Washington (4)  ·  Australasian Gastro-Intestinal Trials Group (3)  ·  Jonsson Comprehensive Cancer Center (3)  ·  SWOG Cancer Research Network (3)  ·  Washington University School of Medicine (3)  ·  AstraZeneca (2)  ·  Canadian Cancer Trials Group (2)  ·  Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest (2)  ·  Mehmet Akce (2)  ·  Stanford University (2)  ·  AGO Research GmbH (1)

Countries

United States (84)  ·  Canada (13)  ·  Germany (6)  ·  Italy (6)  ·  Spain (6)  ·  Australia (5)  ·  Netherlands (4)  ·  South Korea (4)  ·  Belgium (2)  ·  China (2)  ·  Norway (2)  ·  Poland (2)  ·  Denmark (1)  ·  Estonia (1)  ·  Finland (1)

Top investigators

Amir A Jazaeri (2)  ·  Jing Zeng (2)  ·  Lillian Siu, MD (2)  ·  Mehmet Akce, MD (2)  ·  Salah-Eddin Al-Batran, Prof. Dr. (2)  ·  Vassiliki Papadimitrakopoulou (2)  ·  A P Chen (1)  ·  Adel Kardosh (1)  ·  Afshin Dowlati (1)  ·  Alain P Algazi, MD (1)  ·  Albert Chang (1)  ·  Albert J Chang (1)  ·  Alberto Sobrero, MD (1)  ·  Albiruni Razak, MD (1)

Results publications

PMID 10673991, PMID 16773629, PMID 17997439, PMID 19097774, PMID 21555688, PMID 23770567, PMID 24209604, PMID 24472710, PMID 24476821, PMID 25428503, PMID 26487582, PMID 26541610, PMID 27140411, PMID 27262113, PMID 27269937, PMID 27324051, PMID 27345655, PMID 27726966, PMID 28078238, PMID 28259287, PMID 28271869, PMID 28337197, PMID 28481359, PMID 28817753, PMID 28885881, PMID 32027845, PMID 32379280, PMID 32379297, PMID 33714009, PMID 34006499, PMID 34389237, PMID 34429332, PMID 34663638, PMID 35033226, PMID 36007218, PMID 36889516, PMID 36912078, PMID 37476372, PMID 38009662, PMID 38127487, PMID 38205877, PMID 38410608, PMID 39178370, PMID 39521433, PMID 39551064, PMID 39631846, PMID 39886125, PMID 39965889, PMID 40466026, PMID 40580957

NIH funding

2018 (3), U10CA180820 (3), U10CA180868 (3), U10CA180888 (3), 2023 (2), 2025 (2), 2014 (1), 2015 (1), P30CA015083 (1), P30CA015704 (1), P30CA016056 (1), P30CA016672 (1), P30CA033572 (1), P30CA043703 (1), P30CA060553 (1)